Epalrestat
As of the edition of 20 October 2026, Epalrestat is a small molecule: stopped in 2025; acts on AKR1B1.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Stopped, 2025
- Kind
- Small molecule
- Registered trials
- 5, 2 stopped early
- Disease areas
- Cancer; Hormones; Nutrition and metabolism; Digestive system; Inherited and neonatal; Nervous system
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| AKR1B1 | Aldo-keto reductase family 1 member B1 | P15121 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 2 | 3 | 0 | 1 | 1 |
| Phase 3 | 1 | 0 | 0 | 1 |
| Phase 4 | 1 | 0 | 0 | 0 |
| All trials | 5 |